Purple Biotech (NASDAQ:PPBT – Get Free Report) posted its quarterly earnings results on Tuesday. The company reported ($0.67) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.88) by $2.21, Zacks reports.
Purple Biotech Trading Down 1.2%
Purple Biotech stock traded down $0.02 during mid-day trading on Tuesday, hitting $1.66. 5,228 shares of the company’s stock were exchanged, compared to its average volume of 463,657. Purple Biotech has a 1-year low of $0.91 and a 1-year high of $8.90. The stock has a 50 day moving average of $1.39 and a two-hundred day moving average of $2.77. The stock has a market cap of $1.54 million, a P/E ratio of -0.07 and a beta of 0.77.
Analyst Ratings Changes
Separately, Weiss Ratings downgraded shares of Purple Biotech from a “sell (e+)” rating to a “sell (e)” rating in a research report on Thursday, October 29th. One investment analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $30.00.
View Our Latest Analysis on Purple Biotech
Purple Biotech Company Profile
Purple Biotech is an Israeli clinical-stage biopharmaceutical company developing treatments intended to address cancer’s immune evasion and resistance to therapy. Formerly known as Kitov Pharmaceuticals, the company adopted the Purple Biotech name in 2020. Its investigational pipeline has included CM24, a monoclonal antibody targeting CEACAM1, and NT219, a small-molecule candidate designed to inhibit IRS1/2 and STAT3 signaling. These programs have been studied in combination with other cancer treatments.
Further Reading
- Five stocks we like better than Purple Biotech
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
- Tyson Foods’ Earnings Beat Hides a Warning for Consumer Staples Dividend Investors
- 3 Stocks in an Overlooked Corner of Infrastructure With Hundreds of Billions at Stake
Receive News & Ratings for Purple Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Purple Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
